ZYBAN 150 MG
BUPROPION HYDROCHLORIDE : 150 MG · DIN 02238441 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is ZYBAN?
ZYBAN 150 MG contains BUPROPION HYDROCHLORIDE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02238441, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZYBAN used for?
Smoking cessation treatment in conjunction with behavioural modification.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is ZYBAN called?
Also recorded in Canada as: 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet [Forfivo] (US), 12 HR bupropion hydrochloride 90 MG / naltrexone hydrochloride 8 MG Extended Release Oral Tablet [Contrave] (US), bupropion hydrochloride 105 MG / dextromethorphan hydrobromide 45 MG Extended Release Oral Tablet [Auvelity] (US), 12 HR bupropion hydrochloride 100 MG Extended Release Oral Tablet [Wellbutrin] (US), 12 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet [Wellbutrin] (US), 12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet [Wellbutrin] (US), 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet [Wellbutrin] (US), 24 HR bupropion hydrochloride 300 MG Extended Release Oral Tablet [Wellbutrin] (US), 24 HR bupropion hydrochloride 450 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 90 MG / naltrexone hydrochloride 8 MG Extended Release Oral Tablet (US), Smoking Cessation 12 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet (US), bupropion hydrochloride 105 MG / dextromethorphan hydrobromide 45 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 100 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet (US), 12 HR bupropion hydrochloride 200 MG Extended Release Oral Tablet (US).
The same molecule, BUPROPION, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bupropion Teva | Latin | Iceland, Sweden |
| Voxra | Latin | Sweden |
| Bupropion Accord | Latin | Sweden |
| Bupropion Bluefish | Latin | Sweden |
| Bupropion Sandoz | Latin | Sweden |
| Bupropion SUN | Latin | Sweden |
| Wellbutrin Retard (Lyfjaver) | Latin | Iceland |
| Bupropion Omet Pharma | Latin | Sweden |
| Bupropion Orion | Latin | Sweden |
| Bupropion Zentiva | Latin | Sweden |
| Wellbutrin Retard | Latin | Iceland |
| Wellbutrin XR (Heilsa) | Latin | Iceland |
| Wellbutrin XR (Lyfjaver) | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02238441 |
|---|---|
| Brand name | ZYBAN |
| Generic / active ingredient | BUPROPION HYDROCHLORIDE : 150 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 150 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX12 BUPROPION |
| AHFS class | 28:16.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Jun-2021 |
| Original market date | 1998-08-10 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02238441 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2238441 |
| Brand name | ZYBAN |
| Active ingredient / INN | BUPROPION HYDROCHLORIDE : 150 MG |
| ATC code | N06AX12 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06 |
| AHFS class | 28:16.04.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | BAUSCH HEALTH, CANADA INC. |
How is it administered?
Start at 150 mg once daily for 3 days, then increase to 150 mg twice daily (at least 8 hours apart). Max 300 mg/day. Swallow whole. Target quit date in second week of treatment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard storage usually 15-30°C, but text refers to Section 11 which is not fully provided).
How is it supplied?
Kit containing 100 blistered tablets.
Which pack is which?
| Strength on the label | 150 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Packaging as described in the monograph | Kit containing 100 blistered tablets. |
| Storage | Not explicitly detailed in provided text (standard storage usually 15-30°C, but text refers to Section 11 which is not fully provided). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity; seizure disorders; bulimia/anorexia nervosa; abrupt withdrawal from alcohol/sedatives; concurrent MAOIs or thioridazine; use of other bupropion-containing products.
Warnings and precautions
Increased risk of self-harm and suicidal thinking. Dose-dependent seizure risk. Avoid in patients with Brugada syndrome. Monitor for hypertension. Do not crush or chew.
What can be used instead?
Other Canadian products sharing ATC code N06AX12 BUPROPION. 9 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ODAN BUPROPION SR | 100 MG | TABLET (EXTENDED-RELEASE) | ODAN LABORATORIES LTD | MARKETED | DIN 02275074 |
| ODAN BUPROPION SR | 150 MG | TABLET (EXTENDED-RELEASE) | ODAN LABORATORIES LTD | MARKETED | DIN 02275082 |
| TARO-BUPROPION XL | 150 MG | TABLET (EXTENDED-RELEASE) | SUN PHARMA CANADA INC | MARKETED | DIN 02475804 |
| TARO-BUPROPION XL | 300 MG | TABLET (EXTENDED-RELEASE) | SUN PHARMA CANADA INC | MARKETED | DIN 02475812 |
| TEVA-BUPROPION XL | 150 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02439654 |
| TEVA-BUPROPION XL | 300 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02439662 |
| WELLBUTRIN XL | 150 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02275090 |
| WELLBUTRIN XL | 300 MG | TABLET (EXTENDED-RELEASE) | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02275104 |
| AVA-BUPROPION SR | 100 MG | TABLET (EXTENDED-RELEASE) | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363399 |
| AVA-BUPROPION SR | 150 MG | TABLET (EXTENDED-RELEASE) | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363402 |
Who else supplies BUPROPION worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BUPROPION appears in 114 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does BUPROPION cost around the world?
BUPROPION is listed on 8 national price registers Nexara tracks, across 88 pack listings published on 8 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Sweden | AIP (pharmacy purchase price) | 9 | 33 | 03 Sep 2026 |
| United States | acquisition | 2 | 26 | 03 Sep 2026 |
| Iceland | max wholesale | 6 | 11 | 02 Sep 2026 |
| Morocco | PPV (public price) | 3 | 11 | 05 Sep 2026 |
| Australia | ex-manufacturer | 1 | 2 | 08 Sep 2026 |
| Greece | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
| Romania | max producer price | 1 | 2 | 03 Sep 2026 |
| South Africa | single exit price | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.